All In Biotech

Drug Trial Radar · NCT05579132

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

203

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.

Conditions

  • Acute Lymphoblastic Leukemia

Interventions

  • MK-1045Drug

    MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Following each consolidation and maintenance cycle, there are treatment-free intervals ranging 2-8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 24 months
  2. Dose Escalation Phase: Number of Participants who Discontinue Study Treatment Due to an AETime frame: Up to approximately 21 months
  3. Dose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to 28 days
  4. Dose Escalation Phase: Maximum Tolerated Dose (MTD) of MK-1045Time frame: Up to approximately 21 months
  5. Phase II: Complete Remission (CR) RateTime frame: Up to approximately 10 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Third Military Medical University ( Site 0008)

    Chongqing, Chongqing Municipality, China · Recruiting

  • Southern Medical University Nanfang Hospital ( Site 0004)

    Guangzhou, Guangdong, China · Recruiting

  • The Second Hospital of Hebei Medical University ( Site 0003)

    Shijiazhuang, Hebei, China · Recruiting

  • The First Hospital of Harbin ( Site 0005)

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital-hematology department ( Site 0002)

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)

    Wuhan, Hubei, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University ( Site 0007)

    Xuzhou, Jiangsu, China · Active not recruiting

  • West China Second University Hospital, Sichuan University ( Site 0011)

    Chengdu, Sichuan, China · Completed

  • Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)

    Hangzhou, Zhejiang, China · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.